Another experiment in an animal model of bladder cancer has shown the anticancer role of Cdk2 activation in palbociclib-treated animals, indicating that the anticancer effect of palbociclib is exerted via Cdk2 activation [97]. This evidence concerns the gene CDK2 and urinary bladder cancer.